giant cell arteritis market size, giant cell arteritis market analysis, giant cell arteritis industry scope, giant cell arteritis market major players, giant cell arteritis market outlook, giant cell arteritis market drivers
How has the giant-cell arteritis market evolved, and where is it heading next?
The giant-cell arteritis market size has grown strongly in recent years. It will grow from $1.07 billion in 2024 to $1.12 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to epidemiological studies, genetic insights, increasing adoption of biologics, improving diagnostic techniques, and development of targeted therapies and biologics.
The giant-cell arteritis market size is expected to see steady growth in the next few years. It will grow to $1.36 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to increasing diagnosis rates, aging population, rising healthcare expenditure, patient advocacy, expansion into new geographic regions. Major trends in the forecast period include advancements in identifying and validating biomarkers, development of therapies targeting specific molecular pathways, adoption of advanced imaging techniques, drug delivery innovations, utilization of AI algorithms for predictive analytics.
Get Your Free Sample of The Global Giant-Cell Arteritis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp
What are the key forces behind the giant-cell arteritis market’s growth in recent years?
Growing emphasis on personalized medicine is expected to propel the growth of the giant-cell arteritis market going forward. Personalized medicine involves tailoring medical treatment to individual characteristics, such as genetics, lifestyle, and environment. Personalized medicine is increasing due to advancements in genomics, biotechnology, and data analytics, enabling targeted therapies that improve treatment efficacy and reduce adverse effects for individuals. Personalized medicine can aid in giant-cell arteritis (GCA) by allowing for targeted therapies based on individual patient factors such as genetic predispositions, immune profiles, and disease manifestations. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based non-profit organization, reported that personalized medicines accounted for over one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year in 2023. During that year, the FDA approved 16 new personalized treatments tailored for rare diseases, a significant increase from six approvals in 2022. Additionally, the approvals in 2023 encompassed seven cancer medications and three treatments for various other diseases and conditions. Therefore, growing emphasis on personalized medicine is driving the growth of the giant-cell arteritis market.
What are the major segments of the giant-cell arteritis market?
The giant-cell arteritis market covered in this report is segmented –
1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin
2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action
3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration
Subsegments:
1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy
2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy
3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids
4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report
Which companies dominate the giant-cell arteritis market?
Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG
What major trends will shape the giant-cell arteritis market during the forecast period?
Major companies operating in the giant-cell arteritis are developing new products, such as biosimilar to expand treatment options and address the unmet medical needs of patients. A biosimilar is a biologic drug that is highly similar to an already approved biological product, with no clinically meaningful differences in terms of safety, purity, and potency. For instance, in April 2024, Fresenius SE & Co. KGaA, a Germany-based healthcare company, launched Tocilizumab-aazg in the US for treating chronic autoimmune diseases. This biosimilar is approved for conditions such as rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. Its approval was based on data from a randomized, double-blind, single-dose, parallel phase 1 trial comparing its pharmacokinetics, safety, and immunogenicity to both US and EU reference tocilizumab in three patient groups.
What are the key regional dynamics of the giant-cell arteritis market, and which region leads in market share?
North America was the largest region in the giant-cell arteritis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Giant-Cell Arteritis Market Report 2025 Offer?
The giant-cell arteritis market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Giant-cell arteritis (GCA) is a type of vasculitis, or inflammation of blood vessels, predominantly affecting medium to large arteries. It commonly involves the temporal arteries, leading to headaches, scalp tenderness, and vision problems. GCA is characterized by inflammation of the vessel walls, potentially leading to serious complications such as blindness or stroke if untreated. Treatment typically involves high-dose corticosteroids to suppress inflammation and prevent complications.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17162
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
